[Skip to Content]
[Skip to Content Landing]
November 1979

Fluphenazine and Social Therapy in the Aftercare of Schizophrenic Patients: Relapse Analyses of a Two-Year Controlled Study of Fluphenazine Decanoate and Fluphenazine Hydrochloride

Author Affiliations

From the Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine (Mr Hogarty and Mr Ulrich), the Psychopharmacology Research Branch, National Institute of Mental Health, Rockville, Md (Dr Schooler), and the Friends Medical Science Research Center, Baltimore (Mr Mussare, Dr Ferro, and Ms Herron).

Arch Gen Psychiatry. 1979;36(12):1283-1294. doi:10.1001/archpsyc.1979.01780120013001

• The ability of long-acting fluphenazine decanoate and oral fluphenazine hydrochloride to forestall relapse among newly discharged schizophrenic patients is examined in the context of high and low degrees of social therapy (ST). A total of 105 patients were randomly assigned to the various treatments and maintained under controlled conditions for two years or until relapse. Relapse rates for all treatments remained traditionally high. Relapse rates for long-acting fluphenazine decanoate and oral fluphenazine hydrochloride are nearly identical in the first year, indicating that drug noncompliance does not adequately explain early schizophrenic relapse. However, patients who received long-acting fluphenazine decanoate and ST have a reduced risk of relapse over time. Relapsers who received long-acting fluphenazine decanoate appeared more affectively disturbed than other relapsers, yet both groups were diagnostically and symptomatically equivalent prior to treatment. Personal discomfort and intrafamilial stress are important predictors.